4.3 Article

Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data

期刊

出版社

WILEY
DOI: 10.1111/cts.13659

关键词

-

向作者/读者索取更多资源

Effective participant recruitment is critical in clinical trials, but inadequate enrollment can lead to delays and compromise scientific integrity. This study analyzed the recruitment rates of early-phase trials and found that pediatric trials have higher recruitment success. Only a small number of trials managed to conclude recruitment, mainly due to efficacy and safety issues or sponsor's strategy. Further research is needed to address this issue.
Effective participant recruitment is a critical challenge in clinical trials. Inadequate enrollment of participants can precipitate delays, escalated costs, and compromise scientific integrity. Despite its relevance, particularly during the early phases, it persists as an obstacle in the field of clinical research. The primary aim of this study was to analyze the recruitment rates of early-phase clinical trials and evaluate their potential associations with key trial characteristics. Using a descriptive and statistical analysis, a research study was conducted based on the early-phase trials registered at the European Clinical Trials Register (EU-CTR), spanning the timeframe from January 2017 to December 2021. Among the 194 trials examined, we found median recruitment rates of 68%. A more detailed exploration revealed a greater level of success in terms of recruitment achievement in pediatric trials when compared to trials involving adults, non-oncologic trials, or those also developed in non-European countries. It is important to underscore that only 69 trials out of the total managed to conclude recruitment, with the most prevalent reason for premature cessation being the presence of efficacy and safety issues or sponsor's strategy. This number can be greatly improved. Despite certain disparities observed in the information within EU-CTR, we have successfully determined the recruitment rates of the studies and established associations with some of the clinical trial characteristics analyzed. Owing to the inherent constraints of this study, further research is warranted to gain a comprehensive understanding of the intricate interplay between trial characteristics and their impact on recruitment rates in early-phase studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

Rocio Montejano, Fernando de la Calle-Prieto, Maria Velasco, Carlos Guijarro, Javier Queiruga-Parada, Maria Jimenez-Gonzalez, Patricia Gonzalez-Ruano, Patricia Martinez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Angela Gutierrez, Miguel Torralba, Ana Diaz-Brasero, Pablo Ryan, Cristina Marcelo, Cristina Diez, Sofia Ibarra, Esperanza Merino, Vicente Estrada, Javier Marcos, Maria Novella, Maria A. Rivera, Manuel Ruiz-Munoz, Marta de Miguel, Llanos Soler, Mikel Del Alamo, Santiago Moreno, Antonio J. Carcas, Alberto M. Borobia, Jose R. Arribas

Summary: This study aimed to evaluate the effectiveness of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment in high-risk patients with severe COVID-19. The results showed that TDF/FTC did not provide significant benefits, while the beneficial effect of baricitinib, as established by prior clinical trials, was confirmed.

CLINICAL INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns

Andres Esteban-Cantos, Javier Rodriguez-Centeno, Juan C. Silla, Pilar Barruz, Fatima Sanchez-Cabo, Gabriel Saiz-Medrano, Julian Nevado, Beatriz Mena-Garay, Maria Jimenez-Gonzalez, Rosa de Miguel, Jose I. Bernardino, Roco Montejano, Julen Cadinanos, Cristina Marcelo, Lucia Gutierrez-Garcia, Patricia Martinez-Martin, Cedrick Wallet, Francois Raffi, Berta Rodes, Jose R. Arribas

Summary: This study investigates the effects of antiretroviral therapy (ART) on HIV-induced epigenetic modifications. It found that ART initiation modified DNA methylation levels at 845 CpG positions, with 49.3% of the changes being restored to the uninfected state. Untreated HIV infection was associated with DNA methylation changes in biological processes regulating the immune system and antiviral responses. Changes in DNA methylation levels after ART initiation were weakly correlated with changes in CD4+ cell counts and the CD4/CD8 ratio.

EBIOMEDICINE (2023)

Article Biotechnology & Applied Microbiology

Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

Ilaria Galgani, Airi Poder, Rain Jogi, Veli-Jukka Anttila, Stefano Milleri, Alberto M. Borobia, Odile Launay, Marco Testa, Daniela Casula, Luca Grassano, Annaelisa Tasciotti, Marie Dozot, Ashwani K. Arora

Summary: This study compared the immune response and safety of administering NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. The results showed that NTHi-Mcat elicited a similar immune response regardless of whether it was administered alone or at different time intervals following RZV. The safety profiles were acceptable without any new safety concerns.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

Article Chemistry, Medicinal

Immune-Mediated Organ-Specific Reactions to COVID-19 Vaccines: A Retrospective Descriptive Study

Carmen Ruiz-Fernandez, Ricardo Cuesta, Susana Martin-Lopez, Javier Guijarro, Arturo Lopez Gomez de las Huertas, Mikel Urroz, Laura Miguel-Berenguel, Miguel Gonzalez-Munoz, Elena Ramirez

Summary: Severe acute respiratory syndrome coronavirus 2 caused the global COVID-19 pandemic and led to the development of COVID-19 vaccines. Delayed hypersensitivity reactions (HRs) have been observed, particularly to the excipients PEG2000 and P80. Lymphocyte transformation tests (LTT) with PEG2000 and P80 were conducted on 23 patients with suspected delayed HRs, and positive results were found in some cases. LTT can serve as a useful tool for identifying excipients as causal agents in HRs to COVID-19 vaccines and can aid in risk stratification for patients with HRs.

PHARMACEUTICALS (2023)

Article Pharmacology & Pharmacy

Impact of systemic corticosteroids on length of hospitalization among patients with COVID-19

Ester Zamarron, Carlos Carpio, Elena Villamanan, Rodolfo Alvarez-Sala, Alberto M. Borobia, Luis Gomez-Carrera, Antonio Buno, M. Concepcion Prados

Summary: The COVID-19 pandemic has led to a need for strategies to release and create new hospital beds due to the high number of admissions. This study assessed the efficacy of systemic corticosteroids in reducing the length of stay in hospitals and compared the effect of 3 different corticosteroids on this outcome.

FARMACIA HOSPITALARIA (2023)

Article Pharmacology & Pharmacy

Impact of systemic corticosteroids on hospital length of stay among patients with COVID-19

Ester Zamarron, Carlos Carpio, Elena Villamanan, Rodolfo Alvarez-Sala, Alberto M. Borobia, Luis Gomez-Carrera, Antonio Buno, Concepcion Prados

Summary: Due to the COVID-19 pandemic, hospitals are facing a capacity threat and have implemented various strategies to create more beds. This study evaluated the effectiveness of systemic corticosteroids in reducing hospital stay and compared the effects of three different corticosteroids. The results showed that systemic corticosteroid treatment, particularly with dexamethasone, was associated with a shorter hospital stay. Overall, the study rated the importance of this finding at 8 out of 10.

FARMACIA HOSPITALARIA (2023)

Article Health Care Sciences & Services

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Julia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Canete, Antonio Barreiro, Luis Gonzalez-Gonzalez, Laia Madrenas, Irina Guell, Bonaventura Clotet, Nuria Izquierdo-Useros, Dalia Raich-Regue, Marcal Gallemi, Julia Blanco, Edwards Pradenas, Benjamin Trinite, Julia G. Prado, Oscar Blanch-Lombarte, Raul Perez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quinones, Xavier Nunez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Marti Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, Jose Molto, Susana Benet, Lucia Bailon, Jose R. Arribas, Alberto M. Borobia, Javier Queiruga Parada, Jorge Navarro-Perez, Maria Jose Forner Giner, Rafael Orti Lucas, Maria del Mar Vazquez Jimenez, Salvador Ona Compan, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Munoz Garcia, Sofia de la Villa Martinez, Sara Rodriguez Fernandez, Teresa Prat, Elia Torroella, Laura Ferrer

Summary: In the interim results of the Phase IIb HH-2 trial, the SARS-CoV-2 protein-based heterodimer vaccine PHH-1V is shown to have a stronger immunogenicity and higher safety compared to the homologous booster BNT162b2. The PHH-1V booster induces a superior neutralizing antibody response against various SARS-CoV-2 variants and also elicits a strong T-cell response.

LANCET REGIONAL HEALTH-EUROPE (2023)

Article Medicine, Research & Experimental

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

Paloma Moraga, Paula Prieto, Almari Conradie, Majda Benhayoun, Vicki Rousell, Maria Davy, Uwe Fuhr, Rosa Antonijoan Arbos, Francisco Abad-Santos, Antonio Portoles, Jolanda Van Duinen, Antonio J. Carcas, Alberto M. Borobia

Summary: First-time-in-human (FTIH) trials are conducted to gather information on the safety, tolerability, pharmacokinetics, and pharmacodynamics of new drugs. In the ERA4TB project, a partnership between public and private entities aims to create a feasibility tool to validate CTUs for FTIH trials. A feasibility form was created to assess CTUs based on key attributes of FTIH trials, and collaboration between industry and academic partners resulted in the establishment of minimal criteria for CTU adherence to GCP and EMA regulations. Five academic CTUs have been accredited for FTIH trials through the certification procedure of the feasibility tool.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Medicine, General & Internal

Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol

Alicia Marin-Candon, Irene Garcia-Garcia, Pedro Arias, Antonio J. Carcas, Lucia Diaz-Garcia, Rosa Feltes Ochoa, Natalia Hernandez Cano, Pedro Herranz Pinto, Maria Jimenez Gonzalez, Eduardo Lopez-Granados, Ana Martinez-Feito, Ander Mayor-Ibarguren, Rocio Rosas-Alonso, Enrique Seco-Meseguer, Alberto M. Borobia

Summary: This study aims to optimize the treatment of atopic dermatitis by using multiomic predictive models to identify biomarkers and develop a response prediction model for ciclosporine therapy.

BMJ OPEN (2023)

暂无数据